Thromboembolic events in Fabry disease and the impact of factor v Leiden

Neurology

Volumn 84, Issue 10, 2015, Pages 1009-1016

  Lenders, Malte ^a   Karabul, Nesrin ^b   Duning, Thomas ^a   Schmitz, Boris ^a   Schelleckes, Michael ^a   Mesters, Rolf ^a   Hense, Hans Werner ^a   Beck, Michael ^b   Brand, Stefan Martin ^a   Brand, Eva ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 5;

ADOLESCENT; ADULT; AGED; ARTICLE; BODY MASS; CEREBROVASCULAR ACCIDENT; CHILD; COHORT ANALYSIS; DEEP VEIN THROMBOSIS; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INVESTIGATIVE PROCEDURES; LIFESPAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT RISK; PERSONAL EXPERIENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SMOKING; TRANSIENT ISCHEMIC ATTACK; COMORBIDITY; GENETICS; ISCHEMIC ATTACK, TRANSIENT; MIDDLE AGED; PRESCHOOL CHILD; PULMONARY EMBOLISM; RISK; STATISTICS AND NUMERICAL DATA; STROKE; VENOUS THROMBOSIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; COMORBIDITY; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; FACTOR V; FEMALE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; PULMONARY EMBOLISM; RISK; STROKE; VENOUS THROMBOSIS; YOUNG ADULT;

EID: 84924358989     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001333     Document Type: Article

References (35)

1. Zarate YA, Hopkin RJ. Fabry's disease. Lancet 2008;372: 1427-1435.
2. Mehta A, Beck M, Elliott P, et al. Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data. Lancet 2009;374: 1986-1996.
3. Moore DF, Kaneski CR, Askari H, Schiffmann R. The cerebral vasculopathy of Fabry disease. J Neurol Sci 2007; 257:258-263.
4. Hughes DA, Mehta AB. Vascular complications of Fabry disease: enzyme replacement and other therapies. Acta Paediatr Suppl 2005;94:28-33.
5. Feldt-Rasmussen U. Fabry disease and early stroke. Stroke Res Treat 2011;2011:615218. doi: 10.4061/2011615218.
6. Vedder AC, Linthorst M, van Breemen MJ, et al. The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. J Inherit Metab Dis 2007;30:68-78.
7. Gupta S, Ries M, Kotsopoulos S, Schiffmann R. The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women. Medicine 2005;84:261-268.
8. Mehta A, Ginsberg L. Natural history of the cerebrovas-cular complications of Fabry disease. Acta Paediatr Suppl 2005;94:24-27.
9. Rosendorff A, Dorfman DM. Activated protein C resis tance and factor V Leiden: a review. Arch Pathol Lab Med 2007;131:866-871.
10. Bushnell CD, Goldstein LB. Diagnostic testing for coagu-lopathies in patients with ischemic stroke. Stroke 2000;31:3067-3078.
11. Juul K, Tybiaerg-Hansen A, Steffensen R, Kofoed S, Jensen G, Nordestgaard BG. Factor V Leiden: The Copenhagen City Heart Study and 2 meta-analyses. Blood 2002;100:3-10.
12. Altarescu G, Moore DF, Schiffmann R. Effect of genetic modifiers on cerebral lesions in Fabry disease. Neurology 2005;64:2148-2150.
13. Tchan M, Sillence D. Fabry disease and factor V Leiden: a potent vascular risk combination. Intern Med J 2011;41: 422-426.
14. Niemann M, Weidemann F. A dangerous combination: Fabry disease and factor V Leiden. Intern Med J 2012;42: 1270-1271.
15. Rolfs A, Martus B, Heuschmann PU, et al. Protocol and methodology of the Stroke in Young Fabry Patients (si-fap1) study: a prospective multicenter European study of 5, 024 young stroke patients aged 18-55 years. Cerebro-vasc Dis 2011;31:253-262.
16. Amarenco P, Bogousslavsky J, Caplan LR, Donnan GA, Hennerici MG. Classification of stroke subtypes. Cerebro-vasc Dis 2009;27:493-501.
17. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31:1281-1357.
18. Krall JM, Uthoff VA, Harley JB. A step-up procedure for selecting variables associated with survival. Biometrics 1975;31:49-57.
19. Crowley J, Hu M. Covariance analysis of heart transplant survival data. J Am Stat Assoc 1977;72:27-36.
20. Viana-Baptista M. Stroke and Fabry disease. J Neurol 2012;259:1019-1028.
21. Sims K, Politei J, Banikazemi M, Lee P. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry. Stroke 2009;40:788-794.
22. Baptista MV, Ferreira S, Pinho-E-Melo T, et al. Mutations of the GLA gene in young patients with stroke: the PORTYSTROKE Study-screening genetic conditions in Portuguese young stroke patients. Stroke 2010;41: 431-436.
23. Shi Q, Chen J, Pongmoragot J, Lanthier S, Saposnik G. Prevalence of Fabry disease in stroke patients: a systematic review and meta-analysis. J Stroke Cerebrovasc Dis 2014; 23:985-992.
24. Mohrenschlager M, Pontz BF, Lanzl I, Podskarbi T, Henkel V, Ring J. Fabry disease: case report with emphasis on enzyme replacement therapy and possible future therapeutic options [in English, German]. J Dtsch Dermatol Ges 2007;5:594-597.
25. Shen Y, Bodary PF, Vargas FB, et al. Alpha-galactosidase A deficiency leads to increased tissue fibrin deposition and thrombosis in mice homozygous for the factor V Leiden mutation. Stroke 2006;37:1106-1108.
26. Heit JA, Sobell JL, Li H, Sommer SS. The incidence of venous thromboembolism among factor V Leiden carriers: a community-based cohort study. J Thromb Haemost 2005;3:305-311.
27. Goldstein LB, Bushnell CD, Adams RJ, et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011;42:517-584.
28. Mehta A, Beck M, Eyskens F, et al. Fabry disease: a review of current management strategies. QJM 2010;103:641-659.
29. German Foundation for Neurology. Interdisciplinary guidelines for diagnosis and treatment of Fabry disease. Available at: www.awmf.org. AWMF guidelines register no. 030/134. Accessed January 26, 2015.
30. Banikazemi M, Bultas J, Waldek S, et al; Fabry Disease Clinical Trial Study Group. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 2007;146:77-86.
31. Rombach SM, Smid BE, Bouwman MG, Linthorst GE, Dijkgraaf MG, Hollak CE. Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain. Orphanet J Rare Dis 2013;8:47.
32. Feriozzi S, Torras J, Cybulla M, et al. The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy. Clin J Am Soc Nephrol 2012;7:60-69.
33. Germain DP, Waldek S, Banikazemi M, et al. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 2007;18:1547-1557.
34. Weidemann F, Niemann M, Breunig F, et al. Long-term effects of enzyme replacement therapy on Fabry cardiomy-opathy: evidence for a better outcome with early treatment. Circulation 2009;119:524-529.
35. Weidemann F, Niemann M, Störk S, et al. Long-term outcome in advanced Fabry disease under causal enzyme replacement therapy: evidence for disease progression towards serious complications. J Intern Med 2013;274: 331-341.